31 / 48
•
Investigator-assessed median PFS was NR (95% CI, NR–NR) in the brigatinib arm and 9.2
months (95% CI, 7.4–12.9 months) in the crizotinib arm (HR, 0.45 [95% CI, 0.30–0.68]; log-rank
P=0.0001)
•
1-year OS probability: brigatinib, 85% (95% CI, 76%–91%); crizotinib, 86% (77%–91%)
Primary Endpoint: BIRC-Assessed PFS
•
Brigatinib met the prespecified threshold for statistical superiority vs crizotinib
Treatment
No. (%) of
Patients
With
Events
Median
PFS
(95% CI)
1-Year PFS,
%
(95% CI)
Brigatinib
(n=137)
36
(26)
NR
(NR–NR)
67
(56–75)
Crizotinib
(n=138)
63
(46)
9.8 months
(9.0–12.9)
43
(32–53)
September 25, 2018, at
NEJM.org. DOI: 10.1056/NEJMoa1810171